课题基金 / 基金详情

Optimizing Chronic Hepatitis C Treatment Using Pharmacogenomic Biomarkers

Optimizing Chronic Hepatitis C Treatment Using Pharmacogenomic Biomarkers
使用药物基因组生物标志物优化慢性丙型肝炎治疗
批准号:
296156
负责人:
Carleton Bruce C
金额:
$32.78万
依托单位国家:
加拿大
项目类别:
Miscellaneous Programs
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-10-01 至 2015-10-01

项目摘要

项目成果

Carleton Bruce C的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Hepatitis C virus (HCV) infection is a global health problem. After 20 or more years of chronic HCV infection, many patients develop liver problems and some will require a liver transplant or die. In Canada it is estimated that more than 250,000 suffer fr
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SEARCH (active Surveillance and Evaluation of Adverse Reactions in Canadian Healthcare) & PREVENT (Pharmacogenomics of Adverse Reaction EVEnts National Team)
  • 批准号:
    379425
  • 项目类别:
    Operating Grants
  • 资助金额:
    $163.91万
  • 财政年份:
    2018
  • 负责人:
    Carleton Bruce C
  • 依托单位:
Severe Cutaneous Adverse Drug Reactions (SCAR) 2019 International Meeting: From Science to Translation
Domperidone to stimulate milk production during lactation and potential risk of serious ventricular arrhythmia and/or sudden cardiac death.
  • 批准号:
    383477
  • 项目类别:
    Miscellaneous Programs
  • 资助金额:
    $37.61万
  • 财政年份:
    2017
  • 负责人:
    Carleton Bruce C
  • 依托单位:
Genomic and Outcomes Databank for Pharmacogenomic and Implementation Studies (GoPGx)
  • 批准号:
    378647
  • 项目类别:
    Operating Grants
  • 资助金额:
    $200.27万
  • 财政年份:
    2017
  • 负责人:
    Carleton Bruce C
  • 依托单位:
海外基金